We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Drug Resistant MCF-7 Cell Lines Also Developed Cross-Resistance to Structurally Unrelated Anticancer Agents.
- Authors
İşeri, Özlem D.; Kars, Meltem D.; Eroğlu, Seçkin; Gündüz, Ufuk
- Abstract
The cells developing resistance to an applied drug may also present cross-resistance to other anticancer drugs which are not applied. In this study, the development of cross-resistance in paclitaxel (MCF-7/Pac), docetaxel (MCF-7/Doc), vincristine (MCF-7/Vinc) and doxorubicin (MCF-7/Dox) resistant MCF-7 cells to selective anticancer drugs, tamoxifen and all trans-retinoic acid (ATRA) were investigated. Combined antiproliferative effects of these drugs in different combinations were also evaluated by checkerboard combination assay. MCF-7/Pac and MCF-7/Doc cells developed cross-resistance to vincristine (13- and 12-folds, respectively) and tamoxifen (3- and 2-folds, respectively). MCF-7/Dox cells developed cross-resistance to paclitaxel (109-fold), docetaxel (10-fold), tamoxifen (2-fold) and ATRA (3-fold). MCF-7/Vinc cells developed cross-resistance to paclitaxel (48-fold), doxorubicin (6-fold) and tamoxifen (2-fold). Combinations of paclitaxel and docetaxel with doxorubicin exerted synergic antiproliferative effect. Tamoxifen had synergic effect with doxorubicin and vincristine. ATRA had indifferent effect with paclitaxel, docetaxel and doxorubicin where it had antagonistic effect with vincristine. The data presented here may provide an insight to assess response of breast tumors to anticancer drug combinations.
- Subjects
DRUG resistance in cancer cells; DRUG therapy; ANTINEOPLASTIC agents; PACLITAXEL; TAMOXIFEN; VINCRISTINE; BREAST tumor treatment; DRUG antagonism; DOXORUBICIN; THERAPEUTICS
- Publication
UHOD: International Journal of Hematology & Oncology / Uluslararasi Hematoloji Onkoloji Dergisi, 2009, Vol 19, Issue 1, p1
- ISSN
1306-133X
- Publication type
Article